1. Home
  2. GUT vs MYGN Comparison

GUT vs MYGN Comparison

Compare GUT & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gabelli Utility Trust (The)

GUT

Gabelli Utility Trust (The)

HOLD

Current Price

$6.07

Market Cap

540.2M

Sector

Finance

ML Signal

HOLD

Logo Myriad Genetics Inc.

MYGN

Myriad Genetics Inc.

HOLD

Current Price

$5.14

Market Cap

481.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GUT
MYGN
Founded
1999
1991
Country
United States
United States
Employees
N/A
2700
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
540.2M
481.6M
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
GUT
MYGN
Price
$6.07
$5.14
Analyst Decision
Hold
Analyst Count
0
9
Target Price
N/A
$8.06
AVG Volume (30 Days)
180.9K
1.3M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
10.93%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$771,400,000.00
Revenue This Year
N/A
$7.19
Revenue Next Year
N/A
$5.64
P/E Ratio
N/A
N/A
Revenue Growth
N/A
2.33
52 Week Low
$4.71
$3.76
52 Week High
$6.20
$11.44

Technical Indicators

Market Signals
Indicator
GUT
MYGN
Relative Strength Index (RSI) 47.53 51.59
Support Level $5.79 $4.82
Resistance Level $6.12 $5.67
Average True Range (ATR) 0.06 0.39
MACD 0.00 0.13
Stochastic Oscillator 32.35 64.60

Price Performance

Historical Comparison
GUT
MYGN

About GUT Gabelli Utility Trust (The)

Gabelli Utility Trust operates as a diversified closed-end investment management company. The fund's primary objective is the long-term growth of capital and income. To achieve its objective, the fund may invest its assets in common stocks and other securities of foreign and domestic companies involved in providing products, services, or equipment for the generation or distribution of electricity, gas, & water; and telecommunications services or infrastructure operations. It invests in various sectors, of which Electric Integrated, Water, Telecommunications, and U.S. Government Obligations and others.

About MYGN Myriad Genetics Inc.

Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.

Share on Social Networks: